Phase I/II Trial of AG-221 in Advanced Hematologic Cancer
Stein EM et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: Results of a Phase 1/2 trial. Proc ASH 2015;Abstract 323.
Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.
|